Maintenance Azacitidine after Myeloablative Allogeneic Hematopoietic Cell Transplantation for Myeloid Malignancies

Background/Objective: Allogeneic hematopoietic cell transplantation (HCT) is a potential curative option for patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) but carries a high risk of relapse. Azacitidine (aza) may enhance the graft-versus-leukemia effect without an increase in graft-versus-host disease (GVHD) and has been evaluated for relapse prevention following HCT with reduced intensity conditioning. Given the poor outcomes associated with relapsed AML and MDS post-HCT, our institution administered maintenance aza to these patients.
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Source Type: research